Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICLE 2022 | Assessing immunotherapies with a novel tumor model using humanized mice

Juliane Mietz, University Of Zurich, Zurich, Switzerland, discusses the creation of a novel tumor model in humanized mice to advance research into cellular immunotherapies. An endogenous immune system was created using hematopoietic progenitor cells (HPCs) sourced from human fetal liver tissue and an immortalized lymphoblastoid cell line (LCL) was produced using tumor tissue derived from donor B-cells infected with the Epstein-Barr virus (EBV). LCL was injected in the humanized mince to assess the functionality of the endogenous immune system and further assays showed increased expression of activation markers such as HLA-DR. The novel mouse model represents a viable alternative to current immunocompromised mouse models. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.